UNASSIGNED: 2594 Background. We have previously described a vaccination procedure with an Autologous Hemoderivative (AH) that in solid @entity5 , including @entity0 , inhibited the progressive disease condition, elicited @entity245 ( @entity245 ) and induced a @entity5 stroma modification in responder @entity1 (E. Lasalvia-Prisco et al, @entity5 Biology _ Therapy, 2003; ASCO 2003). The present study describes the disease and @entity245 evolution in responder vaccinated @entity1 . METHODS: Thirty metastatic (1-3 sites), chemotherapy resistant (3-lines) @entity0 @entity1 (Ages: 38-72 y.o.) in progressive disease (RECIST assessment) were included. Written informed consents and institutional ethical committee approval were accomplished. The included @entity1 were vaccinated with AH with the procedure above referred. After 6 months, 11 @entity1 were responders (Stable disease + Partial Remission) and @entity245 -positive response elicited by AH (>=  5mm). When progressive disease reappeared, a second vaccination with a second AH was performed. Follow up of these 11 responder @entity1 was analyzed (RECIST assessment and intradermal @entity245 -test elicited with the first and second AH). RESULTS: Progressive Disease reappeared in 10 responder @entity1 7-14 months after vaccination. In these 10 @entity1 , a second AH was freshly prepared and a second vaccination was performed. Previously to the second vaccination, @entity245 response elicited by intradermal test with the first AH persisted positive in 9, and it was negative in all 10 when it was performed with the second AH. Six month after the second vaccination with the new AH, a second @entity5 (Stable disease + Partial Remission) was evident in 8 @entity1 and the @entity245 response elicited with the second AH was positive in 7 of them. ConclusionsResults are consistent with a @entity5 immuno-escape by changes in the neo-antigen library and the feasibility of re-vaccination with an updated AH containing neo-antigens delivered from the @entity5 to the blood. [Table: see text].

@entity0 : Updated vaccination with an autologous hemoderivative in changing XXXX antigen library.

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancer', 'Tumor-Growth response', 'tumors'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity245 :: ('MESH:D002658', 'Disease') :: ['DTH', 'Delayed Type Hypersensibility'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']
@entity5 :: (MESH:D009369,Disease) :: ['tumor']
